Moderna announced top-line results from its Phase 3 trial of the mRNA-1010 seasonal influenza vaccine, showing a 26.6% relative vaccine efficacy compared to a licensed standard-dose shot in adults aged 50 and older. The vaccine demonstrated strong protection across all targeted flu strains and had a safety profile consistent with previous studies. These results lay the groundwork for upcoming regulatory submissions and advance Moderna's efforts toward flu and potential COVID-19 combination vaccines.